Meliodays is a pharmaceutical company developing MelioOne®, the first intrauterine device specifically for period pain relief. This combination product uses a slow-release mechanism to deliver a localized, low dose of an established pain medicine over two years. The goal is to provide effective, non-hormonal management for dysmenorrhea while minimizing systemic exposure.
Funding
Funding not disclosed
Founders
Product
Problem
A significant portion of the menstruating population experiences severe period pain, often leading to disruption of daily activities. Existing treatments, including oral NSAIDs and hormonal or copper IUDs, present limitations such as systemic side effects, cycle disruption, or increased bleeding and cramping.
Solution
Meliodays is developing MelioOne®, a novel intrauterine device (IUD) designed as a non-hormonal, non-contraceptive therapeutic for menstrual pain. MelioOne® utilizes a polymer-based technology for sustained, localized delivery of NSAIDs directly to the uterus, targeting inflammation at its source. This approach aims to provide up to two years of continuous pain relief, equivalent to a low daily dose of an oral painkiller, while mitigating the systemic side effects associated with oral NSAID consumption and the drawbacks of current IUDs. The device is classified as a combination product, integrating medical device and pharmacological components, adhering to stringent regulatory standards for safety and efficacy.
Target Audience
The primary target audience includes individuals experiencing severe menstrual pain who seek effective, long-term, non-hormonal pain relief. This also extends to healthcare providers, such as gynecologists and obstetricians, looking for innovative therapeutic options for dysmenorrhea.
Features
- Non-hormonal, non-contraceptive IUD for targeted period pain management.
- Sustained-release polymer technology for localized NSAID delivery over a two-year period.
- Dosage equivalent to 400mg Celecoxib per year, administered locally to the uterus.
- Addresses dysmenorrhea by normalizing prostaglandin production at the site of inflammation.
- Avoids systemic side effects common with oral NSAIDs, such as gastrointestinal and cardiovascular strain.
- Differentiates from hormonal IUDs by preventing side effects like ovarian cysts and mood alterations.
- Offers an alternative to copper IUDs, which can exacerbate bleeding and cramping.
- Leverages the uterine first-pass effect for enhanced drug concentration at the target site with reduced systemic absorption.
- Combination product classification (medical device and pharmaceutical agent) subject to rigorous regulatory oversight.